What the study found: Tucidinostat plus R-CHOP improved event-free survival in newly diagnosed MYC/BCL2 double-expressor lymphoma (DEL), a subtype of diffuse large B-cell lymphoma defined by coexpression of MYC and BCL2. The treatment also produced a higher complete response rate than R-CHOP alone.
Why the authors say this matters: The authors conclude that this trial provides evidence for a new first-line therapeutic approach for this high-risk population and that it is the first to show benefit from an epigenetic modulator in diffuse large B-cell lymphoma. Epigenetic modulator means a drug that affects how genes are regulated rather than changing the DNA sequence.
What the researchers tested: The researchers ran a randomized, double-blind, placebo-controlled phase 3 trial at 40 centers in China. A total of 423 eligible patients were assigned to oral tucidinostat or matching placebo, each given with 6 cycles of R-CHOP; patients with a complete response could then receive maintenance tucidinostat or placebo for up to 24 weeks.
What worked and what didn't: The tucidinostat group had a lower risk of disease progression, relapse after complete response, death, or starting new therapy for residual disease than the placebo group, with a hazard ratio of 0.72 and a 2-year event-free survival rate of 60.3% versus 50.5%. Complete response was 73.0% with tucidinostat and 61.8% with placebo. More toxicity was seen with tucidinostat, but the abstract says it was generally manageable with supportive care.
What to keep in mind: The summary provided does not describe detailed limitations beyond the study design and setting. The trial was conducted in China, and the abstract does not give subgroup results or longer-term outcomes beyond the reported follow-up.
Key points
- Tucidinostat plus R-CHOP improved event-free survival in patients with newly diagnosed MYC/BCL2 double-expressor lymphoma.
- The 2-year event-free survival rate was 60.3% with tucidinostat versus 50.5% with placebo.
- Complete response occurred in 73.0% of the tucidinostat group and 61.8% of the placebo group.
- The trial enrolled 423 patients at 40 centers in China and used a randomized, double-blind, placebo-controlled phase 3 design.
- More toxicity occurred with tucidinostat, but it was described as generally manageable with supportive care.
Disclosure
- Research title:
- Tucidinostat plus R-CHOP improved event-free survival in DEL
- Authors:
- Peng-Peng Xu, Yu-Qin Song, Jian-Zhen Shen, Qing-Qing Cai, Hui Zhou, Li-Ling Zhang, Ying Xiang, Xiu-Hua Sun, Wei Yang, Zhi-Hua Yao, Hongmei Jing, Shujuan Wen, Jie Jin, Hong‐Wei Xue, Hong Cen, Kaiyang Ding, Zhengming Jin, Lu Liu, Xiaojing Xing, Lan-Fang Li, Ming Hou, Lu Liu, M Zhang, Wen‐Yu Li, Ou Bai, Ru Feng, Zun-Min Zhu, Hui-Jing Wu, Li-Ping Su, L Gao, F Li, W R Huang, Peng Liu, Yan X, Ying Zhao, Hang Su, Xielan Zhao, Rong Fu, Hong Liu, Wen-Yu Shi, Hui-Zhi Li, Bo Chen, Zhiqiang Ning, Jun Zhu, Wei-Li Zhao
- Institutions:
- Ruijin Hospital, Shanghai Institute of Hematology, Peking University, Peking University Cancer Hospital, Fujian Medical University, Union Hospital, Sun Yat-sen University, Sun Yat-sen University Cancer Center, Hunan Cancer Hospital, Wuhan Union Hospital, Chongqing University, Chongqing Cancer Hospital, Dalian Medical University, Second Affiliated Hospital of Dalian Medical University, China Medical University, Henan Cancer Hospital, Peking University Third Hospital, Xinjiang Medical University, Tumor Hospital of Xinjiang Medical University, First Affiliated Hospital Zhejiang University, Qingdao University, Affiliated Hospital of Qingdao University, Guangxi Medical University, Soochow University, First Affiliated Hospital of Soochow University, Hebei Medical University, Fourth Hospital of Hebei Medical University, The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing Medical University, Liaoning Cancer Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital, Qilu Hospital of Shandong University, First Affiliated Hospital of Zhengzhou University, Guangdong Provincial People's Hospital, Jilin University, First Hospital of Jilin University, Nanfang Hospital, Southern Medical University, Henan Provincial People's Hospital, Hubei Cancer Hospital, Shanxi Provincial Cancer Hospital, Army Medical University, Second Affiliated Hospital of Chongqing Medical University, Nanchang University, First Affiliated Hospital of Nanchang University, Chinese PLA General Hospital, Fudan University, Zhongshan Hospital, The First Affiliated Hospital, Sun Yat-sen University, First Hospital of China Medical University, First People's Hospital of Foshan, Central South University, Xiangya Hospital Central South University, Tianjin Medical University General Hospital, Nantong University, Affiliated Hospital of Nantong University, Shenzhen Chipscreen Biosciences Co.
- Publication date:
- 2026-04-22
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with peer-reviewed research without reading academic papers — one filtered digest, every Friday.